Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

Infection and inflammation are associated with downregulation of hepatic and extrahepatic cytochrome P450s as well as other drug‐metabolizing enzymes and transporters. We review the genesis of inflammatory reactions and discuss the relevance of the inflammation‐related regulation of cytochrome P450 enzymes to clinical drug–disease and drug–drug interactions. An understanding of the enzyme specificity and mechanisms of regulation will allow us to make better decisions about adjusting drug dosage regimens when a patient's inflammatory status changes.

[1]  E. Morgan,et al.  Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins* , 2006, Journal of Biological Chemistry.

[2]  Edward T. Morgan,et al.  Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.

[3]  T. A. Richardson,et al.  Hepatic Cytochrome P450 Gene Regulation during Endotoxin-Induced Inflammation in Nuclear Receptor Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[4]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[5]  Micheline Piquette-Miller,et al.  Regulation of drug transporters during infection and inflammation. , 2007, Molecular interventions.

[6]  Q. Chen,et al.  Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. , 2000, Archives of biochemistry and biophysics.

[7]  Wei Wei,et al.  Lipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome P450 3a11. , 2006, European journal of pharmacology.

[8]  B. Blumberg,et al.  Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. , 2006, The Journal of clinical investigation.

[9]  E. Morgan,et al.  Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. , 2008, Free radical biology & medicine.

[10]  J. Castell,et al.  Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. Clarke,et al.  Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing , 2008, Expert opinion on drug metabolism & toxicology.

[12]  T. A. Richardson,et al.  Regulation of Hepatic Cytochrome P450 Expression in Mice with Intestinal or Systemic Infections of Citrobacter rodentium , 2009, Drug Metabolism and Disposition.

[13]  S. Shioda,et al.  Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. , 2007, European journal of pharmacology.

[14]  P. Beaune,et al.  Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. , 1999, Biochemical pharmacology.

[15]  A. Kashuba,et al.  Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[16]  W. Pierson,et al.  Altered theophylline clearance during an influenza B outbreak. , 1982, Pediatrics.

[17]  M. Chaluvadi,et al.  TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. , 2009, Biochemical pharmacology.

[18]  T. A. Richardson,et al.  HEPATIC AND RENAL CYTOCHROME P450 GENE REGULATION DURING CITROBACTER RODENTIUM INFECTION IN WILD-TYPE AND TOLL-LIKE RECEPTOR 4 MUTANT MICE , 2006, Drug Metabolism and Disposition.

[19]  T. A. Richardson,et al.  Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.

[20]  S. Ghosh,et al.  NF-κB and the immune response , 2006, Oncogene.

[21]  Wei Wei,et al.  Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. , 2004, Free radical biology & medicine.

[22]  P. Heinrich,et al.  Hepatic cytochrome P450 down‐regulation during aseptic inflammation in the mouse is interleukin 6 dependent , 2000, Hepatology.

[23]  N. Tindberg,et al.  A novel lipopolysaccharide‐modulated Jun binding repressor in intron 2 of CYP2E1 , 2004, Journal of neurochemistry.

[24]  J. Pascussi,et al.  Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? , 2006, European journal of cancer.

[25]  M. Gallo,et al.  Ah Receptor and NF-κB Interactions, a Potential Mechanism for Dioxin Toxicity* , 1999, The Journal of Biological Chemistry.

[26]  Wen Xie,et al.  Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. , 2006, The Journal of biological chemistry.

[27]  S. Ghosh,et al.  NF-kappaB and the immune response. , 2006, Oncogene.

[28]  K. Renton.  Cytochrome P450 regulation and drug biotransformation during inflammation and infection. , 2004, Current drug metabolism.

[29]  M. Gallo,et al.  Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. , 1999, The Journal of biological chemistry.

[30]  Sun-Mee Lee,et al.  Vitamins C and E protect hepatic cytochrome P450 dysfunction induced by polymicrobial sepsis. , 2006, European journal of pharmacology.

[31]  I. Mahmood,et al.  Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies , 2007, Journal of clinical pharmacology.

[32]  Micheline Piquette-Miller,et al.  Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer , 2008, Drug Metabolism and Disposition.

[33]  M. Peuchmaur,et al.  Impact of inflammation on the duodenal mRNA expression of CYP3A and P‐glycoprotein in children with Crohn's disease , 2006, Inflammatory bowel diseases.